|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q4 FY2014
As of Dec 31, 2014
|
Q4 FY2013
As of Dec 31, 2013
|
Q1 FY2013
As of Mar 31, 2013
|
Q1 FY2012
As of Mar 31, 2012
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Current assets | |||||||||||||||
| Cash | |||||||||||||||
| Accounts receivable, net (note 7 and 21(d)) | |||||||||||||||
| Accounts receivable | |||||||||||||||
| Unbilled revenue (note 6 and 15(d)) | |||||||||||||||
| Contract assets | |||||||||||||||
| Inventories | |||||||||||||||
| Prepaid expenses and deposits | |||||||||||||||
| Investment in and advances to unconsolidated joint venture (note 11) | |||||||||||||||
| Assets held for sale | |||||||||||||||
| Total current assets | |||||||||||||||
| Property, plant and equipment, net of accumulated depreciation $276,185 (2018 – $248,885) | |||||||||||||||
| Property, plant and equipment | |||||||||||||||
| Operating lease right-of-use assets | |||||||||||||||
| Investments in affiliates and joint ventures | |||||||||||||||
| Intangible assets | |||||||||||||||
| Other assets | |||||||||||||||
| Goodwill (note 13) | |||||||||||||||
| Deferred tax assets | |||||||||||||||
| Total assets | |||||||||||||||
| Liabilities and shareholders' equity | |||||||||||||||
| Current liabilities | |||||||||||||||
| Accounts payable | |||||||||||||||
| Accrued liabilities | |||||||||||||||
| Contract liabilities | |||||||||||||||
| Current portion of finance lease obligations | |||||||||||||||
| Current portion of long-term debt | |||||||||||||||
| Current portion of contingent obligations | |||||||||||||||
| Current portion of operating lease liabilities | |||||||||||||||
| Total current liabilities | |||||||||||||||
| Derivative financial instruments (note 16(a)) | |||||||||||||||
| Finance lease obligations | |||||||||||||||
| Long-term debt | |||||||||||||||
| Contingent obligations | |||||||||||||||
| Operating lease liabilities | |||||||||||||||
| Other long-term obligations | |||||||||||||||
| Deferred tax liabilities | |||||||||||||||
| Total liabilities | |||||||||||||||
| Shareholders' equity | |||||||||||||||
| Common shares (authorized – unlimited number of voting common shares; issued and outstanding – December 31, 2025 - 28,821,481 (December 31, 2024 – 27,704,450)) | |||||||||||||||
| Treasury shares (December 31, 2025 - 871,244 (December 31, 2024 - 1,000,328)) | |||||||||||||||
| Additional paid-in capital | |||||||||||||||
| Retained earnings | |||||||||||||||
| Accumulated other comprehensive income (loss) | |||||||||||||||
| Shareholders' equity | |||||||||||||||
| Total liabilities and shareholders' equity | |||||||||||||||
Loading...